Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial
Li Ni(Baylor College of Medicine), Dao Wen Wang(Tongji Hospital), Chene Li(Tongji Hospital), Jianping Weng(University of Science and Technology of China), Lujin Wu(Tongji Hospital), Xiaowen Hu(Lanzhou University), Yongxiang Yi(Nanjing University of Chinese Medicine), Jianping Zuo(China University of Mining and Technology), Runhua Zhang(Yunnan University), Jianping Zhao(Xinjiang University), Zhichao Xiao(Tongji Hospital), Xizhen Xu(Tongji Hospital), Hong Wang(Huazhong University of Science and Technology), Dan Li(Tongji Hospital), Chang Xu, Chen Chen(Tongji Hospital), Ling Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Wen Zheng(Tongji Hospital), Wei Tang(Yunnan University), Wei Huang(Sichuan University), Haisheng Wang(Central South University), Yujian Liu(North Sichuan Medical University), Yanyan Chen(China Medical University), Jinliang Li(Palo Alto University), Hualiang Jiang(Shanghai Institute of Materia Medica), Zongzhe Li(Tongji Hospital), Jialin Duan(Northwestern Polytechnical University)
Cited by 49
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence of Diabetes among Men and Women in China
|New England Journal of Medicine|2010|3.1k
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
|Journal of Allergy and Clinical Immunology|2020|2.4k
Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis
|Journal of Medical Virology|2020|1.9k